Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01953822
Other study ID # 116239
Secondary ID
Status Completed
Phase N/A
First received September 26, 2013
Last updated December 23, 2016
Start date October 2013
Est. completion date August 2014

Study information

Verified date December 2016
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Independent Scientific Advisory Committee (ISAC)
Study type Observational

Clinical Trial Summary

This is an observational cohort study to assess the risk of autoimmune disease(s) within 12 months of receiving the first dose of Cervarix® in the exposed cohort and over a comparable period in the unexposed cohorts.

This is an alternative study by GSK using the CPRD database in the UK to fulfil the US FDA safety commitment. The UK has had sufficient Cervarix® vaccination coverage during the period mid-September 2008 to 2011 to allow suitable data to be collected.


Description:

GSK's vaccine Cervarix® protects against Human Papilloma Virus Types-16 and 18-related pre-cancerous lesions. GSK is committed by the US Food and Drug Administration (FDA) to conduct a safety study to evaluate the incidence of new neurological and eye-related autoimmune diseases and other pre-specified autoimmune diseases in subjects receiving Cervarix® in the US. Because of the very low Cervarix® uptake in the US, the observational GSK study to address this commitment is due to be stopped, as it will take too long to recruit the target subjects.

The unexposed male cohorts will be enrolled in order to assess a possible change over time in the incidence rate of new onset of autoimmune disease(s) (NOAD) in the UK Clinical Practice Research Datalink General Practitioner OnLine database (CPRD GOLD) independent of Cervarix® introduction. The cohorts will be frequency matched for the age (age class of one year) and practice region identifier at reference date (age at first dose of Cervarix).

Additionally, the reference date (time = 0) for the vaccinated (exposed) cohort will be the date of the first dose of Cervarix® recorded in CPRD GOLD. The reference date for the unexposed (unvaccinated) cohorts will be a date randomly selected among the reference dates of the exposed subjects and minus 3 years for the historical cohorts.

The other observational study model is a self-control case-series (SCCS) analysis for confirmed NOAD in the exposed female cohort, using a risk period of one year after the first Cervarix® dose, a control period of one year and a six month buffer period between risk and control periods.

Human Papillomavirus Bivalent (Types 16 and 18) vaccine (recombinant) exposed cohort was investigated between 1-SEP-2008 and 31-AUG-2010.

The unexposed concurrent male cohort was investigated between 1-SEP-2008 and 31-AUG-2010.

Unexposed historical female and male cohorts were investigated between 1-SEP-2005 and 31-AUG-2007.


Recruitment information / eligibility

Status Completed
Enrollment 1053
Est. completion date August 2014
Est. primary completion date August 2014
Accepts healthy volunteers No
Gender Both
Age group 9 Years to 25 Years
Eligibility Inclusion Criteria:

Note: Other vaccines are allowed in this study regardless of the time of administration and the time interval between subsequent doses.

Inclusion criteria for the exposed female cohort:

- Female aged from 9 to 25 years at the reference date (01 September 2008 through 31 August 2010).

- Recorded in the CPRD GOLD for at least 12 months before the reference date.

- The first dose of Cervarix received between 01 September 2008 through 31 August 2010, Full date (day/month/year) of Cervarix vaccination(s) available.

- Subject defined as acceptable in CPRD GOLD.

Inclusion criteria for the unexposed historical female cohort:

- Female aged 9 to 25 years at the reference date (01 September 2005 through 31 August 2007).

- Recorded in the CPRD GOLD for at least 12 months before the reference date.

- Subject defined as acceptable in CPRD GOLD.

Inclusion criteria for the unexposed concurrent male cohort:

- Male aged 9 to 25 years at the reference date (01 September 2008 through 31 August 2010).

- Recorded in the CPRD GOLD for at least 12 months before the reference date.

- Subject defined as acceptable in CPRD GOLD.

Inclusion criteria for the unexposed historical male cohort:

- Male aged 9 to 25 years at the reference date (01 September 2005 through 31 August 2007).

- Recorded in the CPRD GOLD for at least 12 months before the reference date.

- Subject defined as acceptable in CPRD GOLD.

Exclusion Criteria:

Exclusion criteria for all cohorts:

- Subjects with a diagnostic code of any auto-immune disease during the year prior to the reference date.

- Subjects who received at least one dose of unspecified HPV vaccine or Gardasil at any time before the reference date.

- Subjects who have been included in the other cohort.

Exclusion criteria for the non-exposed cohorts:

• Subjects who received any dose of Cervarix at any time before the reference date.

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


Intervention

Other:
Data collection
Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of new onset of confirmed autoimmune disease for neuroinflammatory/ophthalmic autoimmune diseases Neuroinflammatory/ophthalmic autoimmune diseases: -Multiple Sclerosis; -Transverse myelitis; -Optic neuritis; -Guillain-Barré syndrome, including Miller Fisher syndrome and other variants; -Other demyelinating diseases: -Acute disseminated encephalomyelitis, including site specific variants: e.g. non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis; -AI peripheral neuropathies and plexopathies (including chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and polyneuropathies associated with monoclonalgammopathy); -Auto-immune uveitis; During the period of 1 year following administration of the first dose of Cervarix® (risk period) among an exposed cohort and during an equivalent time period in the unexposed cohorts No
Primary Occurrence of new onset of confirmed autoimmune disease for other autoimmune diseases Other autoimmune diseases: -Systemic lupus erythematous; -Autoimmune (AI) disease with rheumatologic conditions: -Rheumatoid arthritis (RA);-Juvenile rheumatoid arthritis (JRA); -Still's disease; -Psoriatic arthritis; -Ankylosing Spondylitis; -AI haematological conditions: -Idiopathic thrombocytopenic purpura (ITP); -AI haemolytic anaemia; -AI endocrine conditions: -Type 1 diabetes mellitus; -AI thyroiditis including Hashimoto's disease, Graves' /Basedows' disease; -Inflammatory bowel / hepatic diseases: -Crohn's diseases; -Ulcerative colitis; -Autoimmune hepatitis; During the period of 1 year following administration of the first dose of Cervarix® (risk period) among an exposed cohort and during an equivalent time period in the unexposed cohorts No
Secondary Occurrence of Guillain Barré syndrome (including Miller Fisher syndrome and other variants), and autoimmune haemolytic anaemia Within 2 months following the administration of the first dose of Cervarix® No
Secondary Occurrence of idiopathic thrombocytopenic purpura (ITP) Within six months following the administration of the first dose of Cervarix® No
Secondary Occurrence of new onset of individual confirmed autoimmune disease Occurrence of multiple sclerosis, transverse myelitis, optic neuritis, other demyelinating diseases, auto-immune uveitis, systemic lupus erythematous (SLE), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), Still's disease, psoriatic arthritis, ankylosing spondylitis, type 1 diabetes mellitus, auto-immune thyroiditis (including Hashimoto's disease, Graves'/Basedows' disease), and inflammatory bowel / hepatic disease (Crohn's disease, ulcerative colitis and autoimmune hepatitis) Within 1 year following the administration of the first dose of Cervarix® No
See also
  Status Clinical Trial Phase
Terminated NCT01290393 - Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
Completed NCT00369824 - Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects Phase 3
Completed NCT00345878 - Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years Phase 3
Completed NCT00947115 - Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects Phase 3
Completed NCT01187927 - Drug Use Investigation for Cervarix® N/A
Completed NCT00169494 - Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18 Phase 3
Completed NCT01190176 - Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects Phase 3
Completed NCT00359619 - Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine Phase 2
Completed NCT00196937 - Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 Phase 3
Completed NCT00534638 - Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents Phase 4
Completed NCT00250276 - Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. Phase 3
Completed NCT01031069 - Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Phase 4
Completed NCT00996125 - Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects Phase 3
Completed NCT00779766 - Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects Phase 3
Completed NCT01153906 - Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination N/A
Completed NCT01207999 - Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer N/A
Completed NCT00693615 - Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females Phase 2
Completed NCT00693966 - Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females Phase 2
Completed NCT00541970 - Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs Phase 1
Completed NCT01627561 - Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old Phase 3